Kiniksa Pharmaceuticals is studying follow-on candidate KPL-387, while ARCALYST is noted as a commercialized treatment.
1 report, 1 independent
Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kiniksa Pharmaceuticals is studying follow-on candidate KPL-387, while ARCALYST is noted as a commercialized treatment.